These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26721226)

  • 1. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
    Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
    J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
    Amling CL; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2001 Apr; 165(4):1146-51. PubMed ID: 11257657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
    J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    J Urol; 2015 May; 193(5):1532-8. PubMed ID: 25463990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.
    Boorjian SA; Tollefson MK; Thompson RH; Rangel LJ; Bergstralh EJ; Karnes RJ
    J Urol; 2012 Nov; 188(5):1761-6. PubMed ID: 22998913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low detectable prostate specific antigen after radical prostatectomy--treat or watch?
    Koulikov D; Mohler MC; Mehedint DC; Attwood K; Wilding GE; Mohler JL
    J Urol; 2014 Nov; 192(5):1390-6. PubMed ID: 24859441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
    Freedland SJ; Sutter ME; Dorey F; Aronson WJ
    Urology; 2003 Feb; 61(2):365-9. PubMed ID: 12597949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
    Matsumoto K; Komatsuda A; Yanai Y; Niwa N; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Oya M
    J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
    J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
    Shinghal R; Yemoto C; McNeal JE; Brooks JD
    Urology; 2003 Feb; 61(2):380-5. PubMed ID: 12597952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.